7/4/26
TABULA RASA HEALTHCARE (TRHC)
Thesis: Recent strategic partnerships and product enhancements are expected to drive user growth and revenue, improving overall market sentiment.
★ Analysts see FY2023 revenue reaching $362M — +20.9% growth in a single year.
Why Revenue Could Accelerate
- 1Recent partnership with a major pharmacy benefit manager expected to increase MedWise users by 25% over the next year.
- 2Implementation of new features in MedWise aimed at improving user engagement, projected to enhance revenue per client by 15%.
- 3Potential regulatory changes could increase demand for medication management solutions, benefiting TRHC's market position.
- 4Healthcare digital transformation
- 5Increased focus on medication safety and management
- 6Adoption rates of MedWise platform among healthcare providers
- 7Changes in regulatory requirements affecting medication management
- 8Partnerships with pharmacy benefit managers (PBMs)
My Notes
- "We are committed to expanding our footprint in the healthcare IT space and enhancing our offerings to meet evolving client needs."
- Moat: TRHC's proprietary technology and established relationships with healthcare providers create a moderate level of competitive advantage.
- growth - Investors looking for companies with innovative solutions in the healthcare sector may find TRHC appealing.
- Interest rates affect TRHC primarily through the cost of capital for expansion and technology investments.
- Watch on earnings: Monthly active users of the MedWise platform, Client acquisition costs, Retention rates of existing clients.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $362M to $416M as recent partnership with a major pharmacy benefit manager expected to increase medwise users by 25% over the next year.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.